secwatch / observer
8-K filed May 11, 2026, 7:59 PM ET ticker HRTX CIK 0000818033
earnings confidence high sentiment neutral materiality 0.60

Heron Q1 net revenue $34.7M (-10.8% YoY); Acute Care up 32%; guidance reaffirmed

HERON THERAPEUTICS, INC. /DE/

2026-Q1 EPS reported -$0.04 revenue$34,711,000
item 2.02item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-26-215752
form_type
8-K
ticker
HRTX
cik
0000818033
company_name
HERON THERAPEUTICS, INC. /DE/
filed_at
2026-05-11T23:59:59+00:00
discovered_at
2026-05-14T18:02:33.785584+00:00
generated_at
2026-05-14T19:22:08.614619+00:00
sec_items
["2.02", "9.01"]
event_type
earnings
sentiment
neutral
materiality_score
0.6
calibrated_materiality_score
0.6
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-26-215752
json_url
https://secwatch.observer/filing/0001193125-26-215752.json
markdown_url
https://secwatch.observer/filing/0001193125-26-215752.md
text_url
https://secwatch.observer/filing/0001193125-26-215752.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/0001193125-26-215752-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/818033/000119312526215752/hrtx-20260511.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

d95ad0384e7a867f1c875a71782ff0593c0225ed

HERON THERAPEUTICS, INC. /DE/ reported the three months ended March 31, 2026 results: revenue $34.7 million. Guidance reaffirmed.

Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million

SEC 8-K Item 2.02 confidence 0.9 SEC evidence

Comparable filings

DAVEY TREE EXPERT CO

Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M

DAVEY TREE EXPERT CO June 1, 2026, 1:50 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million

Comparable filing

Exchange Act, unless such subsequent filing specifically references this Form 8-K. --- EX-99.1 (EX-99.1) --- To Our Shareholders, The Company’s first quarter 2026 revenue of $435.8 million increased slightly from the record first quarter 2025 revenue by $1.0 million, or 0.2%. This growth was driven by consistent demand in the Utility segment, where revenue

Filing page SEC filing

DXYN

Dixie Group Q1 2026 net income $1.4M vs loss of $1.6M YoY; sales down 5.7%

DIXIE GROUP INC May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million

Comparable filing

2026) -- The Dixie Group, Inc. (OTCQB: DXYN) today reported financial results for the quarter ended March 28, 2026. For the first quarter of 2026, the Company had net sales of $59,380,000 as compared to $62,990,000 in the same quarter of 2025. The Company had an operating income of $3,264,000 in the first quarter of 2026 compared to an operating income of $11,000

Filing page SEC filing

SNDA

Sonida Senior Living reports Q1 net loss of $41.2M; revenue up 37% on CHP acquisition

SONIDA SENIOR LIVING, INC. May 11, 2026, 7:59 PM ET earnings Items 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million

Comparable filing

Sonida Senior Living Announces First Quarter 2026 Results DALLAS, Texas – May 11, 2026 – Sonida Senior Living, Inc. (the “Company,” “Sonida,” “we,” “our,” or “us”) (NYSE: SNDA), a leading owner, operator and investor of senior housing communities, today announced its results for the first quarter ended March 31, 2026.

Filing page SEC filing

EXPI

eXp World Holdings Q1 revenue $1.0B (+5% YoY), net loss narrows to $(5.1M), Adj. EBITDA $4.1M (+88%)

eXp World Holdings, Inc. May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million

Comparable filing

the company's scale and our focus on operational efficiency across eXp World Holdings,” said Jesse Hill, Chief Financial Officer of eXp World Holdings. “We generated revenue of $1.0 billion and Adjusted EBITDA of $4.1 million, an 88% improvement that further strengthened our financial position. More recently, we executed the strategic NextHome acquisition using cash

Filing page SEC filing

BATRA

Atlanta Braves Holdings Q1 revenue up 53% to $72M; operating loss narrows to $41M

Atlanta Braves Holdings, Inc. May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million

Comparable filing

Total revenue grew to $72 million in the first quarter of 2026, up 53% from the prior year period.

Filing page SEC filing

SBH

Sally Beauty Q2 sales up 2.3%; GAAP EPS $0.43 beats year-ago $0.38; guidance range narrowed

Sally Beauty Holdings, Inc. May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million

Comparable filing

Consolidated net sales of $903 million, an increase of 2.3% compared to the prior year; • Consolidated comparable sales growth of 1.3%; • Global e-commerce sales increased 13% to $108 million, representing 12% of net sales; • GAAP gross margin expansion of 70 basis points to 52.7%; • Adjusted Gross Margin expansion of 80 basis points to 52.8%; • GAAP selling, general and administrative expenses of $404 million, an increase of $14 million compared to the prior year; • Adjusted Selling, General and Administrative Expenses of $404 million, an increase of $20 million compared to the prior year; • GAAP operating earnings of $72 million and GAAP operating margin of 8.0%; • Adjusted Operating Earnings of $73 million and Adjusted Operating Margin of 8.1%; • GAAP diluted net earnings per share of $0.43, an increase of 13% compared to the prior year;

Filing page SEC filing

APC

ARKO Petroleum Q1 net income $8.1M ($4.5M), Adj. EBITDA $36.4M ($30.9M); completes IPO

ARKO Petroleum Corp. May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million

Comparable filing

announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Key Highlights (vs. Year-Ago Period) 1,2 • Net income for the quarter increased to $8.1 million compared to $4.5 million. • Adjusted EBITDA for the quarter increased to $36.4 million compared to $30.9 million. • Net cash provided by operating activities for the quarter was

Filing page SEC filing

HAIN

Hain Celestial reports Q3 FY2026 earnings; detailed figures not included in filing excerpt

HAIN CELESTIAL GROUP INC May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million

Comparable filing

On May 11, 2026, The Hain Celestial Group, Inc. (the “Company”) issued a press release announcing financial results for its third quarter ended March 31, 2026.

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-26-215752
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.